Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis
Go back to Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 516.34 +3.08 (0.60%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $513.26 | 52 Week High | $134.71 | |||
| Open | $518.35 | 52 Week Low | $73.31 | |||
| Day High | $519.07 | P/E | N/A | |||
| Day Low | $510.20 | EPS | $-1.98 | |||
| Volume | 899,949 | |||||
